Baguley BC - Search Results

1

Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).

Portier CJ, Armstrong BK, Baguley BC, Baur X, Belyaev I, Bellé R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM, Carpenter DO, Carpenter HM, López-Carrillo L, Clapp R, Cocco P, Consonni D, Comba P, Craft E, Dalvie MA, Davis D, Demers PA, De Roos AJ, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, Hauptmann M, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Rodriguez T, Röösli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PT, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DD, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou SF. Portier CJ, et al. Among authors: baguley bc. J Epidemiol Community Health. 2016 Aug;70(8):741-5. doi: 10.1136/jech-2015-207005. Epub 2016 Mar 3. J Epidemiol Community Health. 2016. PMID: 26941213 Free PMC article. No abstract available.

2

Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.

Zhou S, Feng X, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Among authors: baguley bc. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):87-97. doi: 10.1016/j.jchromb.2004.06.009. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 15282097

3

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Among authors: baguley bc. Invest New Drugs. 2002 Aug;20(3):281-95. doi: 10.1023/a:1016215015530. Invest New Drugs. 2002. PMID: 12201491 Review.

4

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Among authors: baguley bc. Biochem Pharmacol. 2003 Jan 1;65(1):109-20. doi: 10.1016/s0006-2952(02)01425-9. Biochem Pharmacol. 2003. PMID: 12473385

5

Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Among authors: baguley bc. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65. doi: 10.1016/s0006-2952(03)00189-8. Biochem Pharmacol. 2003. PMID: 12781337

6

Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.

Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC. Zhou SF, et al. Among authors: baguley bc. Xenobiotica. 2001 May;31(5):277-93. doi: 10.1080/00498250110043544. Xenobiotica. 2001. PMID: 11491389

7

Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.

Zhou S, Feng X, Kestell P, Paxton JW, Baguley BC, Chan E. Zhou S, et al. Among authors: baguley bc. Eur J Pharm Sci. 2005 Apr;24(5):513-24. doi: 10.1016/j.ejps.2005.01.006. Eur J Pharm Sci. 2005. PMID: 15784341

8

Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC. Harvey VJ, et al. Among authors: baguley bc. Eur J Cancer. 1991;27(12):1617-20. doi: 10.1016/0277-5379(91)90427-f. Eur J Cancer. 1991. PMID: 1664218

9

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley BC. Leung EY, et al. Among authors: baguley bc. PLoS One. 2014 Aug 29;9(8):e105792. doi: 10.1371/journal.pone.0105792. eCollection 2014. PLoS One. 2014. PMID: 25170609 Free PMC article.

10

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.

Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Screnci D, et al. Among authors: baguley bc. Br J Cancer. 2000 Feb;82(4):966-72. doi: 10.1054/bjoc.1999.1026. Br J Cancer. 2000. PMID: 10732773 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

427 results

Search Page